SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doctor Zeus who wrote (2933)2/24/2011 3:14:15 AM
From: tuck   of 3158
 
Not going to say this munch of Calistoga for $375 million would make it a lot less likely that Gilead would munch Vertex, but maybe a little. Simply because of the use of cash and the distraction. Pretty small, a munch of Vertex is still doable . . . anyhow, Calistoga is a PI3K specialist, a different area for Gilead, which had an unsuccessful foray into oncology once already. They've dipped their toe back in those waters with GS 6624, a monoclonal antibody in P1. This is putting a couple of more toes in . . .

calistogapharma.com

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News